SynthesisNeurotoxicity research2012
Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review.
Synthesis in Neurotoxicity research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02577224 (A Randomised Controlled Trial to Explore the Effectiveness and Cost-effectiveness of a Patient-initiated Botulinum Toxin Treatment Model for Blepharospasm and Hemifacial Spasm Compared to Treatment as Usual), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised Controlled Trial to Explore the Effectiveness and Cost-effectiveness of a Patient-initiated Botulinum Toxin Treatment Model for Blepharospasm and Hemifacial Spasm Compared to Treatment as Usual
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis.Neurotoxicity research · 2016Pooled it
- A patient-initiated treatment model for blepharospasm and hemifacial spasm: a randomized controlled trial.BMC neurology · 2022Trial
- Trial
- Does botulinum toxin affect psycho-social aspects in dystonia?Journal of neural transmission (Vienna, Austria : 1996) · 2024Article
- Outcome of pallidal deep brain stimulation for treating isolated orofacial dystonia.Acta neurochirurgica · 2022Article
- Clinical Features and Evolution of Blepharospasm: A Multicenter International Cohort and Systematic Literature Review.Dystonia (Lausanne, Switzerland) · 2022Article
- Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice.Clinical parkinsonism & related disorders · 2020Article
- Treatment of blepharospasm and Meige's syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice.Journal of neurology · 2020Observational
- How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study.Journal of neurology · 2019Observational
- Treatment of cervical dystonia with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice.Journal of neurology · 2019Observational
- Article
- Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers.The journal of headache and pain · 2017Article
- Long-Term Abobotulinumtoxin A Treatment of Cervical Dystonia.Neurotoxicity research · 2017Article
- Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results of a long-term treatment.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Article
- Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy.Frontiers in neurology · 2017Article
- Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement.Journal of neurology · 2015Review
- Patient considerations in the treatment of cervical dystonia: focus on botulinum toxin type A.Patient preference and adherence · 2015Review
- Update on treatments for dystonia.Current neurology and neuroscience reports · 2014Review
- Diffuse decreased gray matter in patients with idiopathic craniocervical dystonia: a voxel-based morphometry study.Frontiers in neurology · 2014Article
- Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm.Tremor and other hyperkinetic movements (New York, N.Y.) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulinum neurotoxins have been shown to be a safe and effective therapeutic option for most forms of focal dystonia, and are now considered to provide the best symptomatic treatment in these disorders. However, only a few papers addressed the long-term efficacy and safety of repeated treatments with this drug. This article reviews the data from clinical trials that have assessed the long-term results of botulinum neurotoxin type A (BoNT-A) and type B in the treatment of the different forms of focal craniocervical dystonia, cervical dystonia (CD), blepharospasm, oromandibular, and laryngeal dystonia. Studies on the long-term effects of BoNT-A therapy have demonstrated that the majority of patients comply with this repeated treatment because they experience a positive and stable effect over time. It is still unclear whether in patients with focal dystonia the mean dose of BoNT-A changes over time. In spite of the wide spectrum of side effects reported to be associated with BoNT-A treatment, there is no evidence of specific side effects due exclusively to the long-term use of such drugs. The only exception to these positive long-term findings is the occurrence of a subgroup of patients with CD who fail to maintain a sustained response after the first or second effective treatment, partly owing to the development of neutralizing antibodies against the toxin. Longitudinal studies aimed at defining the risk factors for this abnormal pattern of response to botulinum toxin treatment are currently being conducted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.